- Home
- TGHL vs QNCX Comparison
TGHL vs QNCX Comparison
Compare TGHL & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGHL | QNCX |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | Singapore | United States |
| Employees | 7 | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 17.5M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | TGHL | QNCX |
|---|---|---|
| Price | $1.15 | $25.20 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 7.5M | 32.0K |
| Earning Date | 05-18-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.12 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $0.08 |
| 52 Week High | $3.80 | $24.59 |
Technical Indicators
Market Signals| Indicator | TGHL | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 64.63 | 88.02 |
| Support Level | $0.37 | $0.68 |
| Resistance Level | $1.70 | N/A |
| Average True Range (ATR) | 0.20 | 1.81 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 51.30 | 83.81 |
Price Performance
Historical ComparisonAbout TGHL The GrowHub Limited Class A Ordinary Shares
The Growhub Ltd operates as the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, the company has developed a multi-faceted approach to address industry challenges. Its business currently comprises two main divisions, which are the Traceability and Authenticity Solutions and Carbon Project Development.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.